TIDMPXS
RNS Number : 3190S
Provexis PLC
25 June 2018
25 June 2018
Provexis plc
Fruitflow(R)+ Omega-3 to launch in Holland & Barrett
Provexis plc ('Provexis' or the 'Company'), the business that
develops, licenses and sells the proprietary, scientifically-proven
Fruitflow(R) heart-health functional food ingredient, is delighted
to announce it has secured a retail listing with Holland &
Barrett for the Company's Fruitflow(R)+ Omega-3 dietary supplement
product.
Holland & Barrett is Europe's largest health and wellbeing
retailer, supplying its customers with a wide range of vitamins,
minerals, health supplements, specialist foods and natural beauty
products.
It is envisaged that the Company's Fruitflow(R)+ Omega-3 dietary
supplement product will be listed in August 2018 in more than 660
Holland & Barrett stores across the UK and Ireland, together
with Holland & Barrett Online, giving Fruitflow(R) and the
Company's Fruitflow(R)+ Omega-3 dietary supplement product
widespread consumer exposure.
Holland & Barrett has an extensive specialist training
programme, unparalleled in the health supplement industry, under
its own 'Natural Health Academy'. Holland & Barrett staff will
be trained to understand and communicate the benefits of
Fruitflow(R)+ Omega-3 to prospective customers in store and
online.
Holland & Barrett's loyalty programme, Rewards for Life, has
over 10 million members in the UK and is free for customers to
join. Holland & Barrett has also recently introduced its
personalised Healthbox service, providing nutritionist recommended
vitamins and supplements to their customers along with health tips.
Holland & Barrett's Rewards for Life programme and their new
Healthbox service will facilitate more direct communications with
their customers, and both are expected to provide opportunities to
highlight the unique benefits of Fruitflow(R)+ Omega-3.
The product listing in August 2018 will be supported by a number
of staff training, consumer marketing and promotional initiatives,
to include Holland & Barrett's in house Healthy magazine and
their website www.hollandandbarrett.com.
Fruitflow(R)+ Omega-3 is a two-in-one supplement in an easy to
take capsule, supporting healthy blood flow and normal heart
function. In May 2009 Fruitflow(R) was the first technology to be
substantiated by the European Food Safety Authority ('EFSA') under
the new Article 13(5) for proprietary and emerging science, and in
December 2009 the European Commission authorised the health claim
'Helps maintain normal platelet aggregation, which contributes to
healthy blood flow'. Omega-3 has a separate, positive European
Commission approved health claim, and the product packaging
reflects these two claims strongly.
Provexis has a long-term Alliance Agreement with DSM Nutritional
Products for Fruitflow(R), which has seen the Company collaborate
with DSM to develop Fruitflow(R) in all major global markets
through sales as an ingredient to brand owners in the food,
beverage and dietary supplement categories.
The Company's Fruitflow(R)+ Omega-3 dietary supplement business
is complementary to its long-term Alliance Agreement with DSM, and
it is supported by DSM, reflecting the continued strength of the
long term relationship between Provexis and DSM and the shared
interest of both companies in seeking to maximise the commercial
returns that can be achieved from Fruitflow(R). The Company's
Fruitflow(R)+ Omega-3 dietary supplement business is expected to
provide the Company with an additional long term income and profit
stream, and all of the revenue and costs attributable to this
listing with Holland & Barrett will accrue to Provexis.
The Company is currently in the process of having a substantial
batch of Fruitflow(R)+ Omega-3 capsules manufactured, along with
some enhanced product packaging which will be better suited to a
retail environment, and it is envisaged that the product will be
launched in Holland & Barrett in August 2018.
Fruitflow(R)+ Omega-3 was launched by the Company in June 2016
through the Company's e-commerce website www.fruitflowplus.com.
In June 2017 the Company secured a listing for the product with
Amazon.co.uk. Further UK sales channel opportunities are currently
being progressed to include listings with some other major UK
retailers, and the Company is actively seeking to launch the
product online into wider international markets to include North
America.
The Company is keen to develop and launch further potential
Fruitflow(R)+ combination product derivatives, to include a
Fruitflow(R)+ nitrates dietary supplement product which would be
supported by the Company's strong patent position in this area.
Fruitflow(R)+ Omega-3 and other Fruitflow(R)+ derivatives will
help to build awareness of Fruitflow(R) in the consumer healthcare
market around the world, across consumers and other potential large
brand owner customers for Fruitflow(R).
Dawson Buck, Chairman of Provexis, commented:
'I am delighted to announce this listing for Fruitflow(R)+
Omega-3 with Holland & Barrett, Europe's largest health and
wellbeing retailer.
The listing will help raise awareness of the proven benefits of
Fruitflow(R) across a substantial consumer audience, and the
company's expanding Fruitflow(R)+ dietary supplement business is
expected to provide the company with an additional long term income
and profit stream. We look forward to working with Holland &
Barrett to maximise recommendation, trial and repeat purchase of
the product.'
A spokesperson for Holland & Barrett commented:
'We are excited to welcome Fruitflow(R)+ Omega-3 into Holland
& Barrett and look forward to explaining its unique benefits to
our customers across our extensive retail network, to include our
online channels. Holland & Barrett seeks to enhance the
well-being of our customers around the world by delivering the
highest quality, best value nutritional supplements and wellness
products. Fruitflow(R)+ Omega-3, with its innovative, natural and
scientifically proven benefits to cardiovascular health, will be an
important addition to our range of Heart and Circulation
products.'
-ends-
For further information please contact:
Provexis plc Tel: 07490 391888
Dawson Buck, Chairman enquiries@provexis.com
Ian Ford, Finance Director
Cenkos Securities plc Tel: 020 7397 8900
Camilla Hume
Notes for editors
About Provexis plc
AIM-listed Provexis is focused on the development, licensing and
sales of its proprietary, scientifically-proven Fruitflow(R)
heart-health functional food ingredient.
In May 2009, the Company's Fruitflow(R) technology was the first
to be substantiated by the European Food Safety Authority ('EFSA')
under the new Article 13(5) for proprietary and emerging science.
In December 2009 the European Commission authorised the health
claim 'Helps maintain normal platelet aggregation, which
contributes to healthy blood flow', which was the first wording to
be authorised under Article 13(5).
In June 2010 it was announced that the Company had entered into
a long-term Alliance Agreement with DSM Nutritional Products to
commercialise Fruitflow(R), and in June 2015 the Company confirmed
it had agreed significantly enhanced financial terms for its
Alliance Agreement with DSM for Fruitflow(R).
The Company's Alliance partner DSM Nutritional Products has
developed the market actively for the Company's novel, patented
Fruitflow(R) heart-health ingredient in all global markets, with
over 50 regional consumer healthcare brands now having been
launched by direct customers of DSM, and with a number of further
regional brands having been launched through DSM's distributor
channels.
An increasing number of further commercial projects have been
initiated by DSM with prospective customers, including some
prospective customers which are part of global businesses, with
good prospects for these projects to be launched as consumer
products. Interest in the technology exists in all major global
markets.
The Company reported in its interim results on 29 December 2017
that the Company and DSM had seen an encouraging increase in brand
awareness and customer interest in Fruitflow(R) in recent months,
with the total projected annual sales value of the prospective
sales pipeline for Fruitflow(R) continuing to increase and standing
then at a further new all-time high level.
In June 2016 the Company launched a high quality dietary
supplement product containing Fruitflow(R) and Omega-3 which is
being sold from a separate, dedicated website www.fruitflowplus.com
on a mail order basis, the product is also available to purchase
from Amazon.co.uk.
The Company conducted a Key Opinion Leaders' roundtable event
for Fruitflow(R) in London in 2016, focussed on raising awareness
of the importance of blood flow in cardiovascular health, and the
effectiveness of dietary antiplatelets. The roundtable was attended
by key scientists from Provexis and DSM, along with a number of
interested health care professionals with close links to the media.
The event was recorded and a video for Fruitflow(R)+ Omega-3
capsules targeting prospective consumers can be seen here
www.youtube.com/watch?v=P3HCSdyupEY&t=48s
The Company and DSM are keen to secure greater medical advocacy
for Fruitflow(R) and the roundtable event forms part of this
strategy.
The roundtable event is being supported by a broader consumer PR
campaign, and the Company's Fruitflow(R)+ Omega-3 dietary
supplement product has featured in a number of recent articles in
the UK national press which can be seen here
www.fruitflowplus.com/fruitflow-in-the-media
The Company has been engaged in a two stage collaboration
agreement with the University of Oslo to undertake further research
into the relationship between Fruitflow(R) and blood pressure
regulation. In December 2016 the Company announced the results from
the second stage of the collaboration, a pilot study which
indicated that a standard dose of Fruitflow(R) in powder format
significantly lowered average 24-hour systolic blood pressure
compared to placebo. Both systolic and diastolic blood pressure
were shown to be significantly lower whilst trial subjects were
awake, a clinically relevant reduction in blood pressure which is
expected to be of interest to a large number of consumers and
patients with a wide range of cardiovascular conditions. In
September 2017 the results from the blood pressure collaboration
were published in the International Journal of Food Sciences and
Nutrition.
In April 2017 the Company announced that it had entered into a
memorandum of understanding with BY-HEALTH Co., Ltd ('BY-HEALTH')
which is intended to result in a research and collaboration
agreement with BY-HEALTH for Fruitflow(R). The Company also
confirmed separately that Provexis and DSM are working with
BY-HEALTH to support the planned launch of some Fruitflow(R) based
products in the Chinese market.
BY-HEALTH is a substantial Chinese listed dietary supplement
business which is currently valued in excess of GBP2.5bn.
Provexis was founded in 1999 and is headquartered in Reading,
Berkshire.
Provexis shares are traded on the AIM market of the London Stock
Exchange under the ticker symbol PXS.
For further information, please visit www.provexis.com
About Holland & Barrett
Holland & Barrett is Europe's largest health and wellness
retailer leading the market with a broad range of vitamins,
supplements, specialist food, sports nutrition and ethical beauty
brands. Established in 1870 it is owned by the Letter One Retail
Group (L1 Retail) and currently operates more than 1,150 stores
worldwide (including 800 in the UK and Ireland) as well as a
rapidly expanding e-commerce business. Holland & Barrett's
4,200 Associates are highly trained in nutrition and supplements,
able to advise customers on their individual needs.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
CNTEAFKLASEPEFF
(END) Dow Jones Newswires
June 25, 2018 02:00 ET (06:00 GMT)
Grafico Azioni Provexis (AQSE:PXS.GB)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Provexis (AQSE:PXS.GB)
Storico
Da Mag 2023 a Mag 2024